for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dr Reddy's Laboratories Ltd

REDY.NS

Latest Trade

5,283.90INR

Change

-2.60(-0.05%)

Volume

697,428

Today's Range

5,234.80

 - 

5,345.00

52 Week Range

3,814.00

 - 

5,515.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
5,286.50
Open
5,315.00
Volume
697,428
3M AVG Volume
22.02
Today's High
5,345.00
Today's Low
5,234.80
52 Week High
5,515.00
52 Week Low
3,814.00
Shares Out (MIL)
165.77
Market Cap (MIL)
875,907.40
Forward P/E
26.96
Dividend (Yield %)
0.47

Next Event

Dividend For RDY.N - 0.3419 USD

Latest Developments

More

Rockwell Announces Collaboration With Dr. Reddy's For Sputnik V Vaccine Roll Out In India

India's Dr.Reddy's Laboratories March-Quarter Consol Net Profit Falls

Merck Announces Voluntary Licensing Agreements With Five Indian Generics Manufacturers To Accelerate And Expand Global Access To Molnupiravir, An Investigational Oral Therapeutic For Treatment O

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dr Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Industry

Biotechnology & Drugs

Contact Info

8-2-337, Road No.3 Banjara Hills

500-034

India

+91.40.49002900

http://www.drreddys.com/

Executive Leadership

Satish Reddy

Chairman of the Board

G. V. Prasad

Co-Chairman of the Board, Managing Director

Erez Israeli

Chief Executive Officer

Parag Agarwal

Chief Financial Officer

Patrick Aghanian

Chief Executive Officer, European Generics

Key Stats

1.86 mean rating - 36 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

153.9K

2020

174.6K

2021

189.7K

2022(E)

235.2K
EPS (INR)

2019

113.090

2020

218.360

2021

115.140

2022(E)

195.957
Price To Earnings (TTM)
45.02
Price To Sales (TTM)
4.60
Price To Book (MRQ)
4.96
Price To Cash Flow (TTM)
27.54
Total Debt To Equity (MRQ)
16.69
LT Debt To Equity (MRQ)
3.57
Return on Investment (TTM)
11.31
Return on Equity (TTM)
7.83

Latest News

Latest News

India's Dr. Reddy's in talks with government to bring Russia's Sputnik Light COVID-19 vaccine

India's Dr. Reddy's Laboratories is in talks with the government to bring Russia's Sputnik Light COVID-19 vaccine into the country, a company spokesperson told Reuters on Monday.

Exclusive: India to get Russia's Sputnik V vaccine only by end-May

India will start receiving Russia's Sputnik V COVID-19 vaccine by end-May, its local distributor Dr. Reddy's Laboratories told Reuters on Thursday, a later than expected schedule that could slow the country's immunisation drive.

India drug regulator asks Dr.Reddy's for more data on Sputnik V COVID-19 vaccine

An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.

Dr.Reddy's seeks Indian emergency use authorization for Russia's Sputnik V vaccine

Indian drugmaker Dr.Reddy's Laboratories said on Friday it has begun the process of filing for emergency use authorization of Russia's Sputnik V COVID-19 vaccine in India.

India's Dr.Reddy's ends study of COVID-19 drug Avigan in Kuwait

Indian drugmaker Dr.Reddy's Laboratories said on Wednesday it had terminated its clinical study of Fujifilm Holdings' COVID-19 treatment Avigan in patients with moderate to severe symptoms in Kuwait.

India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints

India hopes five locally-tested vaccines will help it to control COVID-19, as those developed by Pfizer <PFE.N> and Moderna <MRNA.O> may not be available to it in big quantities soon.

Indian shares rise as Dr.Reddy's boosts pharma stocks

Indian shares opened higher on Friday, boosted by pharma stocks after Dr.Reddy's Laboratories Ltd hit a record high, and as broader Asian markets advanced on hopes of more monetary support from central banks.

Russia seals another deal to supply and test its coronavirus vaccine abroad

Russia's sovereign wealth fund will supply 100 million doses of its potential coronavirus vaccine to Indian drug company Dr Reddy's Laboratories, the fund said on Wednesday, as Moscow speeds up plans to distribute its shot abroad.

Russia to sell COVID-19 vaccine to India's Dr. Reddy's Laboratories

Russia's sovereign wealth fund said on Wednesday it will supply India's Dr. Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against COVID-19 once it receives regulatory approval in India.

Sensex, Nifty rise on banking, IT boost; Dr. Reddy's hits five-week high

Indian shares on Wednesday notched their best closing levels in nearly three weeks, boosted by gains in large-cap banks and IT firms, while drugmaker Dr. Reddy's Laboratories jumped on a deal with a Russian fund to cooperate on Moscow's vaccine trials.

Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment

Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia.

Fujifilm to partner with Dr. Reddy's to sell Avigan overseas as COVID-19 treatment

Fujifilm Holdings Corp said on Wednesday it was partnering with Dr Reddy's Laboratories to sell the anti-flu drug Avigan in India and elsewhere to treat COVID-19, the respiratory disease caused by the coronavirus.

BRIEF-Dr.Reddy's Laboratories Says Launch Of Abiraterone Acetate Tablets In U.S. Market

* DR.REDDY'S LABORATORIES LTD SAYS LAUNCH OF ABIRATERONE ACETATE TABLETS USP, 250 MG IN U.S. MARKET. Source text for Eikon: Further company coverage:

BRIEF-Dr. Reddy's Laboratories Enters Into Licensing Agreement With Gilead Sciences For Remdesivir

* DR. REDDY'S LABORATORIES ENTERS INTO A LICENSING AGREEMENT WITH GILEAD SCIENCES FOR REMDESIVIR

BRIEF-Dr.Reddy's Labs Announces Launch Of Colchicine Tablets In U.S. Market

* ANNOUNCES LAUNCH OF COLCHICINE TABLETS USP, 0.6 MG IN U.S. MARKET Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Completes Acquisition Of Some Business Divisions Of Wockhardt

* COMPLETES ACQUISITION OF SELECT BUSINESS DIVISIONS OF WOCKHARDT Source text for Eikon: Further company coverage:

BRIEF-Midatech Pharma Enters Into Research Collaboration With Dr Reddy's

* MIDATECH PHARMA - ENTERED INTO A RESEARCH COLLABORATION WITH DR REDDY'S Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Labs Gets EIR From U.S. FDA For Medchal-Malkajgiri Facility

* INSPECTION CLASSIFICATION OF MEDCHAL-MALKAJGIRI FACILITY DETERMINED AS "NO ACTION INDICATED" Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Re-Appoints G V Prasad As Whole-Time Director Designated As Co-Chairman, MD

* RE-APPOINTS G V PRASAD AS WHOLE-TIME DIRECTOR DESIGNATED AS CO-CHAIRMAN AND MD FOR FURTHER PERIOD OF 5 YEARS Source text for Eikon: Further company coverage:

BRIEF-India's Dr.Reddy's Laboratories March Qtr Consol Profit Rises

* MARCH QUARTER CONSOL PROFIT 7.64 BILLION RUPEES VERSUS PROFIT OF 4.34 BILLION RUPEES YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up